TECH OFFER

Platform Technology for Single, Sustained-release Combination Drug to Improve Compliance

KEY INFORMATION

TECHNOLOGY CATEGORY:
Personal Care - Nutrition & Health Supplements
Healthcare - Pharmaceuticals & Therapeutics
Show more >
TECHNOLOGY READINESS LEVEL (TRL):
LOCATION:
Singapore
ID NUMBER:
TO174352

TECHNOLOGY OVERVIEW

Patients with certain conditions such as Parkinson’s Disease are required to take medication several times daily. Polypharmacy has been associated with greater health care costs and an increased risk of adverse drug events (ADEs), drug-interactions, and medication non-adherence amongst many other negative consequences.

This technology platform reformulates commercial pharmaceuticals with poor oral bioavailability profiles to cut the frequency of administering medication and improve treatment outcomes in patients.

TECHNOLOGY FEATURES & SPECIFICATIONS

The technology platform consists of proprietary multiple drug encapsulation technology and, extended and tunable release drug profile of various drugs.

The encapsulation technology leverages on floating technology to prolong gastric-retention time of drugs. The stomach then acts as reservoir and allow for slow absorption and extended release of drugs. Different drugs i.e., hydrophilic and hydrophobic, can be formulated into one single drug capsule and released uniformly.

Clinical pipeline includes candidates for Parkinson’s Disease, cardiovascular disease, and infectious disease currently at pre-clinical stage.

 

POTENTIAL APPLICATIONS

Therapeutics

  • As multiple-drug-in-one capsule or improved drug profile to decrease the need for frequent drug administration and improve medical adherence i.e., one drug instead of Stalevo-Sinemet combi up to 6 times a day for Parkinson’s Disease.

Nutraceuticals and Supplements

  • Technology can also be used to encapsulate natural and other related compounds for tunable, sustained release of supplements or nutraceuticals with more than one ingredient

Market Trends & Opportunities

Treatment market value for PD is expected to rise to US$11.5billion by 2029 at a CAGR of 12.6%.  In addition, as a platform technology, this formulation seeks to improve patient medication compliance by providing sustained release of polypharmacies for the management of chronic diseases. Medical non-compliance in the USA alone costs the health care system $300 billion annually.

Unique Value Proposition

Decreases the need for multiple medications several times a day and ADEs, and healthcare cost; improves medical adherence. For PD patients, this technology will also mitigate levodopa-induced dyskinesia, which affects 90% of PD patients in the latter years of their treatment.

RELATED TECH OFFERS
AI for End-To-End Carbon Accounting and Management
A Novel ‘Red Wine’ Dragon Fruit-Derived Alcoholic Beverage
Proprietary Probiotic Strain of Bifidobacterium longum for Infant Health
Proprietary Postbiotic Strain (heat-killed Lactobacillus paracasei) for Immune Health
Maximising Cell Cultivation With Low Cost 3D Scaffolding
Efficient Green Method to Process Poultry Feather into Hydrolysable Protein
Plant-Derived Nano-delivery Technology to Improve Bioavailability of Actives
RadiLogic: Bringing AI into Radiology
Customisable Non-charging Material for Electrostatic Mitigation in Powder Processing
Clinically validated mobile-based digital psychotherapy for stress and mental wellbeing